mupadolimab   Click here for help

GtoPdb Ligand ID: 11758

Synonyms: CPI-006 | CPI006 | CPX-006 [1] | CPX006
Compound class: Antibody
Comment: Mupadolimab (CPI-006) is a humanised IgG1-κ anti-CD73 (Ecto-5'-Nucleotidase; NT5E) monoclonal antibody that was developed by Corvus Pharmaceuticals as an immunostimulant, originally for oncology use. It functionally inhibits production of immunosuppressive adenosine in the tumour microenvironment, plus binding to CD73 on B cells leads to their activation (including increased antibody production). Corvus had initiated clinical investigation of mupadolimab for potential benefit in COVID-19 patients, but their phase 3 study was terminated, and as of mid-October 2021 there is no mention of this approach on their pipeline webpage (link here).
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11944 mupadolimab
Synonyms Click here for help
CPI-006 | CPI006 | CPX-006 [1] | CPX006
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1212
Other databases
GtoPdb PubChem SID 458923793
Search PubMed clinical trials mupadolimab
Search PubMed titles mupadolimab
Search PubMed titles/abstracts mupadolimab